Trial · NCT04812626
Intralesional Triamcinolone Acetonide and Its Combination With 5-fluorouracil in Keloids and Hypertrophic Scars
NCT04812626, Not applicable, Completed, B.P. Koirala Institute of Health Sciences
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intralesional Triamcinolone Acetonide and Its Combination With 5-fluorouracil in Keloids and Hypertrophic Scars. Trials, record NCT04812626. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04812626
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intralesional Triamcinolone Acetonide and Its Combination With 5-fluorouracil in Keloids and Hypertrophic Scars
- NCT number
- NCT04812626
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 66 participants, actual
- Lead sponsor
- B.P. Koirala Institute of Health Sciences
- Conditions
- Scar Keloid
- Interventions
- 5-Fluorouracil
- First posted
- 2021-03-23
- Last updated
- 2022-04-07
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of change in height of scar pre and post treatment in each groups | Starting of treatment to 12 weeks follow up of treatment | Compare the change in height in millimeter of scar pre and post treatment in percentages in each treatment groups |
| Primary | Percentage of reduction in The Patient and Observer Scar Assessment Score) score in two treatment groups | Starting of treatment to 12 weeks follow up of treatment | Compare the reduction in The Patient and Observer Scar Assessment Score from baseline to 12 week follow up in each group in percentage |
| Primary | Percentage of change in Vancouver Scar Scale score in two treatment groups | Starting of treatment to 12 weeks follow up of treatment | Compare the change in Vancouver Scar Scale from baseline to 12 week follow up in each group in percentage |
| Primary | Percentage of good to excellent subjective improvement in two groups combination with 5-flurouracil in the treatment of keloids and hypertrophic scars at 12 weeks follow up | Starting of treatment to 12 weeks follow up of treatment | Compare the good to excellent improvement (\>50% subjective improvement) in the scars in two treatment groups in percentage |
| Secondary | Percentages of Side effects of treatment groups | Starting of treatment to 12 weeks follow up of treatment | Compare the percentages of side effects of treatment between the group |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04812626
GET https://conductscience.org/api/trials/v1/NCT04812626/registered